Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785216 | 0.91 | PPM1B (0.33) | L3MBTL1 | |
| SCHEMBL3786147 | 0.88 | ALDH1A1 (0.31) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL3789382 | 0.87 | ALDH1A1 (0.39) | SMN1; SMN2ATMKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3780168 | 0.85 | SMN1; SMN2 (0.35) | SMN1; SMN2ATMKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL3794014 | 0.79 | ALDH1A1 (0.34) | KMT2AALDH1A1MEN1 | |
| SCHEMBL3788867 | 0.77 | ALDH1A1 (0.41) | SMN1; SMN2L3MBTL1ALDH1A1HPGDMAPT | |
| SCHEMBL15707668 | 0.76 | TP53 (0.33) | KMT2AALDH1A1MEN1 | |
| SCHEMBL3789516 | 0.76 | PPM1B (0.36) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL15707638 | 0.75 | PPM1B (0.40) | SMN1; SMN2ATMKMT2AALDH1A1MEN1 | |
| SCHEMBL3793851 | 0.73 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696366-B2 | Production process of bifunctional epoxy monomer by selective oxidation of diolefin compound | SHOWA DENKO K.K. (JP) | 2010-04-13 | — | — | US | disclosed |
| EP-1891031-B1 | PRODUCTION PROCESS OF BIFUNCTIONAL EPOXY MONOMER BY SELECTIVE OXIDATION OF DIOLEFIN COMPOUND | SHOWA DENKO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20090030217-A1 | PRODUCTION PROCESS OF BIFUNCTIONAL EPOXY MONOMER BY SELECTIVE OXIDATION OF DIOLEFIN COMPOUND | SHOWA DENKO K.K. (JP) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030217-A1 | PRODUCTION PROCESS OF BIFUNCTIONAL EPOXY MONOMER BY SELECTIVE OXIDATION OF DIOLEFIN COMPOUND | DUOX2, DUOX1, DDT | SMN1; SMN2 2870/4885ATM 3185/4885KMT2A 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.